Brief: Revive Therapeutics announces US FDA acceptance
06/07/2016 13:01
July 6 (Reuters) - Revive Therapeutics Ltd RVV.V :
* Revive Therapeutics Ltd announces US FDA acceptance of IND
of Bucillamine for the treatment of cystinuria
* Says "look forward to initiating this phase 2 study
shortly"
Source text for Eikon: ID:nMKWSzZkKa
Further company coverage: RVV.V
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure